Epidemiology of adenosarcoma and the inverse probability of treatment weighting (IPTW) adjusted survival analysis of lymph node dissection in uterine adenosarcoma.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
23 Sep 2022
23 Sep 2022
Historique:
entrez:
5
10
2022
pubmed:
6
10
2022
medline:
12
10
2022
Statut:
ppublish
Résumé
The objective for the study was to analysis the epidemiology of adenosarcoma, and independent prognostic factors and impact of lymph node dissection (LND) of uterine adenosarcoma. Cases of patients with primary adenosarcoma were obtained from the Surveillance, Epidemiology, and End Results (SEER) database from 2000 to 2016. Overall survival was analyzed by the Kaplan-Meier method and log-rank test. The differences in baseline covariates between the 2 groups were adjusted by inverse probability of treatment weighting method. The prognostic factors were identified by univariate and multivariate Cox regression analysis and hazard ratio and 95% confidence interval (CI) of covariates were also estimated. 1129 patients with pathological primary adenosarcoma between 2000 and 2016 were identified from the surveillance, epidemiology, and end results database. The only 4 patients were male. 1027 patients with primary uterine adenosarcoma, and 53.1% underwent LND and only 3.5% patients were with positive lymph node. Age, marital status, largest tumor size, tumor grade, T stage and chemotherapy were significantly correlated with survival. Race, tumor number, LND, and radiotherapy did not affect overall survival in patients. Inverse probability of treatment weighting-adjusted K-M curve showed that LND did not improve survival and lymph node metastasis (LNM) did not affect survival. The majority of primary adenosarcoma patients are female with high incidence of uterus and rare incidence of distant metastasis. Age, marital status, tumor size, T stage, grade, and chemotherapy are independent prognostic factors of uterine adenosarcoma. LNM was not a significant prognostic risk factor, and LND did not benefit survival.
Identifiants
pubmed: 36197202
doi: 10.1097/MD.0000000000030607
pii: 00005792-202209230-00048
pmc: PMC9509147
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30607Informations de copyright
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
BMC Cancer. 2018 Feb 5;18(1):134
pubmed: 29402239
Int J Gynecol Cancer. 2018 Sep;28(7):1297-1310
pubmed: 30044322
Cancer. 1974 Oct;34(4):1138-49
pubmed: 4371193
Int J Gynaecol Obstet. 2009 Mar;104(3):177-8
pubmed: 19135669
Int J Biol Sci. 2020 Jan 1;16(3):388-395
pubmed: 32015676
Gynecol Oncol. 2017 Mar;144(3):524-530
pubmed: 28109626
Gynecol Oncol. 2001 Oct;83(1):89-94
pubmed: 11585418
Hum Pathol. 1990 Apr;21(4):363-81
pubmed: 2156771
Hum Pathol. 2009 Nov;40(11):1571-85
pubmed: 19540555
Crit Rev Oncol Hematol. 2008 Feb;65(2):129-42
pubmed: 17706430
Gynecol Oncol. 2014 Dec;135(3):455-61
pubmed: 25449308
Oncol Res Treat. 2018;41(11):693-696
pubmed: 30326467
Gynecol Oncol. 2010 Nov;119(2):305-8
pubmed: 20688363
J Gynecol Oncol. 2010 Jun;21(2):125-8
pubmed: 20613904
Int J Gynecol Cancer. 1999 Jan;9(1):37-43
pubmed: 11240741
Hum Pathol. 2018 Mar;73:108-113
pubmed: 29079182
Gynecol Oncol. 2013 Apr;129(1):140-4
pubmed: 23283300
Gynecol Oncol. 2016 Dec;143(3):636-641
pubmed: 27771166
Expert Rev Anticancer Ther. 2018 Nov;18(11):1093-1100
pubmed: 30169984
Virchows Arch. 2020 Sep;477(3):461-466
pubmed: 32219513
Int J Gynecol Pathol. 1992;11(2):75-88
pubmed: 1316323
Gynecol Oncol. 2010 Jan;116(1):131-9
pubmed: 19853898
Eur J Gynaecol Oncol. 2014;35(6):617-20
pubmed: 25556263
Curr Oncol Rep. 2016 Nov;18(11):68
pubmed: 27718181
Cancers (Basel). 2021 Nov 19;13(22):
pubmed: 34830960